Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Veracyte (NASDAQ:VCYT) is the #1 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Veracyte (NASDAQ:VCYT) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Veracyte (NASDAQ:VCYT) has a Due Diligence Score of 59, which is 34 points higher than the biotech industry average of 25.

VCYT passed 19 out of 33 due diligence checks and has strong fundamentals. Veracyte has seen its stock lose -2.67% over the past year, overperforming other biotech stocks by 32 percentage points.

Veracyte has an average 1 year price target of $45.17, an upside of 37.75% from Veracyte's current stock price of $32.79.

Veracyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Veracyte, 50% have issued a Strong Buy rating, 16.67% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 16.67% have issued a Strong Sell.

Pharming Group Nv (NASDAQ:PHAR) is the #2 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pharming Group Nv (NASDAQ:PHAR) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: C.

Pharming Group Nv (NASDAQ:PHAR) has a Due Diligence Score of 30, which is 5 points higher than the biotech industry average of 25.

PHAR passed 9 out of 33 due diligence checks and has average fundamentals. Pharming Group Nv has seen its stock return 86.1% over the past year, overperforming other biotech stocks by 121 percentage points.

Pharming Group Nv has an average 1 year price target of $39.00, an upside of 140.3% from Pharming Group Nv's current stock price of $16.23.

Pharming Group Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Pharming Group Nv, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the #3 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Jazz Pharmaceuticals (NASDAQ:JAZZ) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: B.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a Due Diligence Score of 16, which is -9 points lower than the biotech industry average of 25. Although this number is below the industry average, our proven quant model rates JAZZ as a "A".

JAZZ passed 5 out of 33 due diligence checks and has weak fundamentals. Jazz Pharmaceuticals has seen its stock return 39.8% over the past year, overperforming other biotech stocks by 74 percentage points.

Jazz Pharmaceuticals has an average 1 year price target of $223.91, an upside of 18.42% from Jazz Pharmaceuticals's current stock price of $189.08.

Jazz Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Jazz Pharmaceuticals, 63.64% have issued a Strong Buy rating, 27.27% have issued a Buy, 9.09% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Novabay Pharmaceuticals (NYSEMKT:NBY) has an annual dividend yield of 281.69%, which is 242 percentage points higher than the biotech industry average of 39.49%.

Novabay Pharmaceuticals's dividend payout ratio of -105.3% indicates that its high dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 21.04%, which is -18 percentage points lower than the biotech industry average of 39.49%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 7.14%, which is -32 percentage points lower than the biotech industry average of 39.49%.

Oramed Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Biotech stocks were up 2.92% in the last day, and up 1.12% over the last week. Sarepta Therapeutics was the among the top gainers in the biotechnology industry, gaining 34.98% yesterday.

Sarepta Therapeutics shares are trading higher after the company announced that early results from Phase 1/2 studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 and SRP-1003 for myotonic dystrophy type 1. Also, the company generated proof-of-concept data for SRP-1001 and SRP-1003.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -16.37% in the past year. It has overperformed other stocks in the biotech industry by 18 percentage points.

Incyte (NASDAQ:INCY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Incyte has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Incyte's stock has gained 48.57% in the past year. It has overperformed other stocks in the biotech industry by 83 percentage points.

Exelixis (NASDAQ:EXEL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Exelixis's stock has gained 13.46% in the past year. It has overperformed other stocks in the biotech industry by 48 percentage points.

63.68% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 67.6% over the next year.

2.4% of biotech stocks have a Zen Rating of A (Strong Buy), 4.37% of biotech stocks are rated B (Buy), 47.38% are rated C (Hold), 34.28% are rated D (Sell), and 11.57% are rated F (Strong Sell).